drug · small molecule
taletrectinib adipate
Marketedupdated 3mo agoby $NUVB Nuvation Bio Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Phase 1 (across all indications), with 2 investigational indications.
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 11, 2030
~3.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jun 3, 2033compositionUS 9187489
- Jun 3, 2033compositionUS 9751887
FDA exclusivities (1)
- Jun 11, 2030NCENew Chemical Entity (5y)3.8y
News(1)
- The OncFive: Top Oncology Articles for the Week of 5/3The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.onclive · 3mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that